This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
ALNYPositive Net Change BMRNNegative Net Change VRTXNegative Net Change CRSPPositive Net Change
biotechnology biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
by Zacks Equity Research
Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up.
GSKPositive Net Change ALNYPositive Net Change GILDNegative Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
New Strong Buy Stocks for February 12th
by Zacks Equity Research
BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025.
BOHNegative Net Change RHNegative Net Change AUBNegative Net Change IMTXNegative Net Change BHRBNegative Net Change
biotechnology finance
Markets Mixed on Powell Testimony, Q4 Earnings
by Mark Vickery
The Fed Chair told the Senate that the U.S. economy was "strong overall," and again asserted that the Fed does not need "to be in a hurry to adjust [its] stance."
CSCONegative Net Change GILDNegative Net Change KGCNegative Net Change ZPositive Net Change LYFTPositive Net Change VRTNegative Net Change DASHNegative Net Change
biotechnology earnings home-buying-apps ride-hailing
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
by Zacks Equity Research
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
ALNYPositive Net Change BMRNNegative Net Change TEVAPositive Net Change AXSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for February 11th
by Zacks Equity Research
FULT, FBNC, DAN, PCRX and OMVKY have been added to the Zacks Rank #1 (Strong Buy) List on February 11, 2025.
DANNegative Net Change PCRXNegative Net Change FBNCPositive Net Change FULTPositive Net Change OMVKYNegative Net Change
biotechnology finance
Best Value Stocks to Buy for February 11th
by Zacks Equity Research
OMVKY, PCRX and EZPW made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 11, 2025.
EZPWNegative Net Change PCRXNegative Net Change OMVKYNegative Net Change
biotechnology
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
by Ekta Bagri
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
ALNYPositive Net Change BIIBNegative Net Change GILDNegative Net Change VRTXNegative Net Change MRNANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in fourth-quarter 2024 in both the United States and International segments.
EXELNegative Net Change SRPTNegative Net Change ZTSPositive Net Change MIRMNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Quest Diagnostics Stock to Gain From Innovation Amid Industry Threats
by Zacks Equity Research
Within brain health, the robust demand for AD-detect blood tests for assessing Alzheimer's disease risk drives solid growth for DGX in the fourth quarter of 2024.
DGXNegative Net Change CAHPositive Net Change RMDNegative Net Change ATECNegative Net Change
biotechnology medical medical-devices
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports fourth-quarter 2024 results.
GILDNegative Net Change VRTXNegative Net Change EXELNegative Net Change SRPTNegative Net Change
biotechnology biotechs earnings pharmaceuticals
ADMA Loses 8.9% in a Month: How Should You Play the Stock?
by Ekta Bagri
ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
by Zacks Equity Research
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change IMVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
TAL Education (TAL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
TALNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
World Acceptance (WRLD) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
WRLDNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
by Zacks Equity Research
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
ALNYPositive Net Change BMRNNegative Net Change DNLINegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.
ALNYPositive Net Change BMYNegative Net Change PFENegative Net Change BMRNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges.
BIAFNegative Net Change
biotechnology biotechs medical
4 PEG-Based GARP Stocks to Stay Ahead in Uncertain Markets
by Urmimala Biswas
Here are four PEG-driven GARP stocks, PPC, EXEL, SYF and UAL, which qualify our screening criteria.
UALNegative Net Change EXELNegative Net Change PPCNegative Net Change SYFPositive Net Change
airlines biotechnology consumer-staples finance medical transportation
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
by Zacks Equity Research
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.
ALNYPositive Net Change BMRNNegative Net Change RAREPositive Net Change CSTLPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
by Zacks Equity Research
GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.
ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change GHRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Blueprint Medicines (BPMC) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
by Zacks Equity Research
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.
ALNYPositive Net Change NVSPositive Net Change PTCTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Feb 6, 2025
by Zacks Equity Research
Companies In The News Are:AMGN, PRU, ATO, SPG.
SPGNegative Net Change AMGNPositive Net Change PRUNegative Net Change ATONegative Net Change
biotechnology insurance reit utilities